1. Home
  2. MRM vs XTLB Comparison

MRM vs XTLB Comparison

Compare MRM & XTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRM
  • XTLB
  • Stock Information
  • Founded
  • MRM 2000
  • XTLB 1993
  • Country
  • MRM Japan
  • XTLB Israel
  • Employees
  • MRM N/A
  • XTLB N/A
  • Industry
  • MRM Other Consumer Services
  • XTLB Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRM Consumer Discretionary
  • XTLB Health Care
  • Exchange
  • MRM Nasdaq
  • XTLB Nasdaq
  • Market Cap
  • MRM 12.2M
  • XTLB 15.6M
  • IPO Year
  • MRM 2020
  • XTLB 2005
  • Fundamental
  • Price
  • MRM $4.00
  • XTLB $2.62
  • Analyst Decision
  • MRM
  • XTLB
  • Analyst Count
  • MRM 0
  • XTLB 0
  • Target Price
  • MRM N/A
  • XTLB N/A
  • AVG Volume (30 Days)
  • MRM 2.1M
  • XTLB 9.4K
  • Earning Date
  • MRM 01-01-0001
  • XTLB 09-24-2024
  • Dividend Yield
  • MRM N/A
  • XTLB N/A
  • EPS Growth
  • MRM N/A
  • XTLB N/A
  • EPS
  • MRM 0.16
  • XTLB N/A
  • Revenue
  • MRM $48,438,179.00
  • XTLB N/A
  • Revenue This Year
  • MRM N/A
  • XTLB N/A
  • Revenue Next Year
  • MRM N/A
  • XTLB N/A
  • P/E Ratio
  • MRM $25.43
  • XTLB N/A
  • Revenue Growth
  • MRM N/A
  • XTLB N/A
  • 52 Week Low
  • MRM $2.27
  • XTLB $0.75
  • 52 Week High
  • MRM $8.39
  • XTLB $4.99
  • Technical
  • Relative Strength Index (RSI)
  • MRM 49.12
  • XTLB 38.92
  • Support Level
  • MRM $3.50
  • XTLB $2.55
  • Resistance Level
  • MRM $4.14
  • XTLB $2.66
  • Average True Range (ATR)
  • MRM 0.69
  • XTLB 0.14
  • MACD
  • MRM -0.07
  • XTLB -0.02
  • Stochastic Oscillator
  • MRM 7.57
  • XTLB -10.34

About MRM MEDIROM Healthcare Technologies Inc.

MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.

About XTLB XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

Share on Social Networks: